clinical trial · NCT04634669
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
Treatment Resistant DepressionMajor Depressive DisorderAXS-05 (dextromethorphan-bupropion)
brief summary
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
started
Sep 23, 2020
primary completion
Feb 18, 2022
completion
Mar 4, 2022
last updated
Jan 28, 2026
detailed description
Eligible subjects must have either completed Study AXS-05-TRD-201 immediately prior to enrollment in this study or meet the DSM-5 criteria for major depressive disorder (MDD) without psychotic features.
official title
An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Treatment Resistant Depression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol